An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia |
| |
| Authors: | Larysa Strilchuk Giuliano Tocci Federica Fogacci |
| |
| Institution: | 1. Department of Therapy and Medical Diagnostics, Lviv National Medical University , Lviv, Ukraine;2. Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant’Andrea Hospital , Rome, Italy;3. Cardiology Unit, IRCCS Neuromed , Pozzilli, Italy  https://orcid.org/0000-0002-0635-4921;4. Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Bologna, Italy https://orcid.org/0000-0001-7853-0042 |
| |
| Abstract: | ABSTRACT Introduction Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of statin users currently reach their lipid goals. In addition, statin treatment alone has relatively low efficacy in reducing other lipid fractions than low-density lipoprotein-cholesterol (LDL-C). In such cases, most guidelines recommend adding the cholesterol absorption inhibitor ezetimibe. |
| |
| Keywords: | Ezetimibe hypercholesterolemia low-density lipoprotein cholesterol (LDL-C) mixed dyslipidaemia rosuvastatin |
|
|
![ORCID Icon]({"type":"image","src":"/templates/jsp/images/orcid.png"} "ORCID Icon")
https://orcid.org/0000-0002-0635-4921;4. Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna , Bologna, Italy